3D Biotek

3D Biotek

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $338K

Overview

Founded in 2004 (incorporated 2007), 3D Biotek is a private, revenue-generating company focused on advanced 3D cell culture technologies. Its product portfolio includes the 3D Insert scaffolds and the 3D Cell Expansion System (3D-CES), targeting the research tools and contract services markets. The company's value proposition centers on providing more physiologically relevant in vitro models to improve drug screening efficiency and enable large-scale cell expansion for therapeutic applications.

Regenerative MedicineOncology

Technology Platform

Precision 3D Micro-Fabrication Technology and Advanced Bio-Manufacturing Technology for creating porous scaffolds and bioreactor systems for 3D cell culture.

Funding History

2
Total raised:$338K
Grant$238K
Grant$100K

Opportunities

The growing demand for physiologically relevant 3D models in drug discovery and the critical need for scalable cell expansion systems in the rapidly advancing cell therapy and exosome therapeutics markets present significant growth opportunities.
Their FDA and ISO certifications position them well for partnerships requiring clinical-grade manufacturing.

Risk Factors

Intense competition from larger life science tool providers and the pace of industry-wide adoption of 3D culture methods pose market risks.
Technological risks include scaling their 3D-CES for robust, cost-effective GMP manufacturing and maintaining differentiation in a crowded field.

Competitive Landscape

3D Biotek competes in the 3D cell culture market against major players like Corning, Thermo Fisher Scientific, and Merck (MilliporeSigma), as well as specialized bioreactor companies. Its differentiation lies in its dedicated focus on 3D microfabrication, integrated expansion systems, and custom manufacturing services for specialized scaffolds.